Search

everythinglearnresearchcommunity

for

Search:↓

Combining scalp photos with hair density and caliber measurements gives a more accurate assessment of hair loss.

Disease-specific tools better assess quality of life in alopecia areata patients.

Baricitinib is effective and safe for severe alopecia areata, working similarly with or without an atopic background.

Diagnosing Polycystic Ovary Syndrome is hard due to varying symptoms, no set criteria, and the need for better tests and education.

Scalp coverage scoring accurately measures hair loss and treatment effectiveness.

Incidental prostate cancer was found in 4.89% of patients undergoing surgery for benign prostatic hyperplasia.

The document sets criteria for diagnosing long-term sexual dysfunctions caused by certain medications.

Consider rare forms of CAH for accurate diagnosis and treatment.

The document concludes that HAIR-AN syndrome should be considered when a patient shows severe hyperandrogenism and insulin resistance after excluding tumors.

Serum steroid profiling, especially 11-deoxycortisol, helps distinguish between adrenocortical carcinoma and adenoma, considering sex and functional status.

Hyperandrogenism is diagnosed using clinical signs, lab tests, and imaging.

An mFG score of 5 or more indicates above-normal hair growth in Southern Chinese women.

The vellus index is a simple, quick, and reliable method to assess and monitor hair growth, especially in hirsutism.

Different types of PCOS in Chinese Han women show varying levels of male hormone and metabolic issues.

Baricitinib significantly regrows hair in severe alopecia areata patients.

A rare case of Cushing's syndrome and pheochromocytoma requires careful re-evaluation to avoid complications.

FAI is a reliable marker for identifying and monitoring hyperandrogenism in obese adolescent females with PCOS.

Nearly half of the classification tools in the National Institute of Health and Clinical Excellence's Clinical Knowledge Summaries might not effectively guide management for general practitioners.

A standardized scoring system is needed to improve model reliability for predicting hair loss in brain tumor patients treated with proton therapy.

A simplified method was introduced to diagnose most hair loss types by examining the patient's history and scalp, with some cases needing further tests.

Estrogen therapy can reduce skin aging but has cancer risks.

Estrogens help reduce skin aging, and SERMs might offer similar benefits without the risks of hormone therapy.

Hair grays due to oxidative stress and fewer functioning melanocytes.

The cause of alopecia areata is likely a mix of genetics, immune system issues, and environmental factors, with more research needed to understand it fully.

Hair color is determined by different melanins and changes with age.

Hair growth is influenced by hormones and goes through different phases; androgens can both promote and inhibit hair growth depending on the body area.

RCS-01 therapy is safe and may improve skin structure by affecting gene expression.

The document concludes that hair loss is complex, affects many people, has limited treatments, and requires more research on its causes and psychological impact.

DPP4-positive fibroblasts play a major role in producing proteins that lead to skin fibrosis.